Ponatinib

From WikiMD.org
Jump to navigation Jump to search

Ponatinib

Ponatinib (pronounced poh-nuh-tih-nib) is a type of tyrosine kinase inhibitor used in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

Etymology

The name "Ponatinib" is derived from the chemical name of the drug, which is 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide. The "Ponat" part of the name is a reference to the chemical structure of the drug, while the "-inib" suffix is common in drugs that inhibit specific proteins or enzymes.

Usage

Ponatinib is used to treat adults with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to or cannot tolerate other treatments. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, helping to stop or slow the spread of cancer cells.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski